New Rules for Cannabis Finance and Capital

Hope usually is considered an asset. But for the cannabis industry, hope quietly has become one of its most dangerous liabilities.

Every operator needs to confront one hard question in 2026: Is hope harming my ability to raise capital? Across the sector, founders are holding onto a familiar set of expectations that may no longer hold true:

• Federal reform will arrive soon enough to rescue margins.
• Investors are just “waiting on the sidelines.”
• The equity markets that existed five years ago will reappear.

This kind of optimism isn’t helping anyone. It isn’t motivating strategic thinking or unlocking new financing avenues. It’s simply delaying shifts the industry desperately needs to make.

The problem isn’t that cannabis is unloved. The problem is that cannabis operators are playing a financing game that no longer exists.

The math has changed: why the equity drought is structural

For years, many plant-touching operators have believed the capital freeze was cyclical. It isn’t. Today’s drought persists because the underlying logic of equity investing collapses under the weight of cannabis-specific constraints.

Start with Internal Revenue Code Section 280E. It doesn’t “compress” earnings; it eliminates them. Investors don’t buy equity for the privilege of funding a tax obligation that consumes 60 to 70 percent of what should be net income. No sophisticated investor can price future earnings when future earnings don’t exist.

Add to that a regulatory environment where pricing, margins, and even basic operating rules shift unpredictably. Equity investment depends on predictable risk and definable upside. Cannabis offers neither. Even in a stronger macro environment, the capital that once poured into the industry was subsidized by somewhat cheap money, novelty, and optimism. Those conditions are gone, and super-high interest rates have only magnified the mismatch between investor expectations and cannabis realities.

The hope capital will come back is built on a misunderstanding. Investors didn’t retreat because of sentiment. They retreated because the math stopped working.

The cost of waiting: when optimism replaces strategy

This is where “toxic hope” comes in. It looks like confidence, but it functions like denial.

Operators tell themselves everything will change once the Secure and Fair Enforcement Regulation (SAFER) Banking Act passes, or once the next election cycle kicks in, or once the market “stabilizes.” But this waiting game is costing founders runway, bargaining power and, in many cases, the opportunity to control their own exit.

I’ve spoken with operators who delayed restructuring for two full years because they expected equity markets to thaw. Others kept refinancing expensive debt under the assumption that a fresh round of investors would bail them out. Others are waiting for some random buyer to come in and pay them all cash (as if). Some are still building pitch decks for investors who simply cannot invest under present conditions — not because they lack interest, but because the risk profile is structurally incompatible with equity economics.

Hope becomes toxic the moment it replaces strategy. In cannabis, that moment arrived years ago. Too many operators just didn’t notice.

The exit myth: why standard investment logic fails

Even now, many founders approach capital strategy as if cannabis behaves like any other emerging consumer industry. However, cannabis remains fundamentally defined by a tax code that penalizes normal business operations, regulatory fragmentation, and restricted capital channels. The industry simply does not fit into the equity investing frameworks into which founders keep trying to insert themselves.

Institutional investors want predictable earnings, a reliable cost structure, and an obvious exit. Cannabis provides none of those. That will remain true until the structural conditions change, and betting a company’s future on political timelines is not strategy.

This is why operators who continue to wait for equity markets to return are not making a rational long-term bet. They’re holding onto a financing model that isn’t coming back in any recognizable form.

Engineering the fix: why your architecture must change

If the traditional model is broken, the question becomes “what actually works?”

This is where alternative structures, especially employee stock-ownership plans (ESOPs), shift the financial landscape. An ESOP is not a tax trick or a feel-good employee incentive program. Done correctly, it’s a structural business re-engineering that removes the single biggest financial drag on cannabis operators: income tax under 280E.

When a cannabis company becomes 100-percent ESOP-owned, its federal income tax obligation and state income tax obligation both drop to zero. That transformation alone changes the trajectory of the company. A business that was barely cash-flow-positive becomes meaningfully profitable. A founder who was boxed out of traditional exits suddenly has a pathway to liquidity without selling to a consolidator or diluting their share of the business into irrelevance. Employees become shareholders, boosting retention and alignment. And, critically, an ESOP does not rely on speculative federal reform or the return of outside equity.

This isn’t optimism. This is architecture. It’s a solution grounded in the tax code.

Overcoming the friction: debunking alternative model myths

Resistance to ESOPs usually is rooted in misconceptions like they’re too complicated, employees will run the company, they depress valuation, or they work only for large companies. None of these presumptions are true. Many founders are uncomfortable moving away from the financing frameworks they’ve always known. They don’t want to consider an alternative because they’re still holding onto hope that the old world will return. But that hope is costing them money, often millions, while the ESOP path creates liquidity, eliminates the tax burden, and preserves long-term upside.

The industry doesn’t need more optimism. It needs more operators willing to confront financial reality and adjust accordingly.

The era of engineering: stop hoping and start acting

Toxic hope has been allowed to shape cannabis capital strategy for too long. It’s time for founders to stop waiting for rescue and start engineering outcomes.

Federal reform may come someday. Investor appetite may improve. But none of that helps operators solve the problems they face today. What helps is embracing structures that work under current law, current markets, and current constraints.

If there’s one message the industry needs to hear in 2026, it’s this:Stop hoping. Start acting. The path forward belongs to those willing to rethink the game, not wait for it to change.

Cannabis finance, clarified

As managing partner at MBO Ventures, serial entrepreneur and prolific angel investor Darren Gleeman assists clients with employee stock ownership plans (ESOPs) and capital management. Previously, he served as managing partner at hedge fund GB Trading. Gleeman holds a patent on ESOP methodology for the cannabis industry and received Green Market Report’s 2024 Top Financial Advisor award.